About this item:

847 Views | 695 Downloads

Author Notes:

Sidney H VanNess: svannes@emory.edu; Michael J Owens: mowens@emory.edu; Clinton D Kilts: sdpcdk@emory.edu

SHV performed all molecular biology, radioligand binding experiments, immunoassays, statistical analysis and drafted the manuscript.

MJO participated in the design of the pharmacological aspects of the study, provided supervision of radioligand binding experiments, and aided in the revision of the manuscript.

CDK participated in the overall design and coordination of the study and aided in the drafting of the manuscript.

All authors read and approved the final manuscript.

The authors would like to acknowledge Dr. Marc Caron for generously supplying the DAT1 starting material, Dr. Allan Levey and Mr. Craig Heilman for assistance with DAT western blots, Dr. Michael Kuhar for advice, and Elyse Katz and Dina Ghoneim for technical assistance.

Subjects:

Research Funding:

This work was supported by the National Institute of Mental Health (R21 MH067939) and by the National Institute on Drug Abuse (T32 DA015040).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Genetics & Heredity
  • GENETICS & HEREDITY
  • DEFICIT HYPERACTIVITY DISORDER
  • REPORTER GENE-EXPRESSION
  • METHYLPHENIDATE RESPONSE
  • 3'-UNTRANSLATED REGION
  • ASSOCIATION
  • CHILDREN
  • VNTR
  • ALLELE
  • POLYMORPHISMS
  • AVAILABILITY

The variable number of tandem repeats element in DATI regulates in vitro dopamine transporter density

Tools:

Journal Title:

BMC Genetics

Volume:

Volume 6

Publisher:

, Pages 55-55

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: A 40-bp variable number of tandem repeats (VNTR) polymorphism exists in the 15th exon of DAT1, the gene encoding the human dopamine transporter (DAT). Though the VNTR resides in a region encoding the 3′ untranslated region (UTR) and does not alter the protein's amino acid sequence, the prevalent 10-repeat variant has shown both linkage and association to Attention Deficit Hyperactivity Disorder (ADHD). In this study, we examined the effects of the DAT1 VNTR on measures of in vitro DAT expression and pharmacology. A series of four DAT1 constructs, each containing the DAT1 coding region, but varying with respect to the downstream presence or content of the 3′UTR, were engineered and stably transfected into an HEK-293 variant using Flp-In integration, an enzyme-mediated, site-specific recombination technology. Results: [3H] Win 35,428 saturation binding assays and DAT immunoblots revealed statistically significant differences in DAT expression attributable to DAT1 genotype. Cells harboring the 10-repeat DAT1 variant were characterized by a Bmax approximately 50% greater than cells with the 9-repeat VNTR; those containing only the DAT1 coding region or the coding region flanked by a truncated 3′UTR resulted in greater DAT density than either of the naturalistic 9- and 10-repeat variants. Competition binding assays showed no statistically significant DAT1 genotype effects on the DAT affinity for methylphenidate, a finding consistent with the positional location of the VNTR. Conclusions: This study identified the DAT1 VNTR as a functional polymorphism and provides an interpretive framework for its association with behavioral phenotypes. © 2005 VanNess et al., licensee BioMed Central Ltd.

Copyright information:

© 2005 VanNess et al; licensee BioMed Central Ltd.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 2.0 Generic License (http://creativecommons.org/licenses/by/2.0/).

Creative Commons License

Export to EndNote